2024-02-13 10:32:18
①Celltrion applies for European product approval for CT-P47 (Roactemra biosimilar) = Celltrion announced on the 13th that it had applied for European product approval for CT-P47 (Roactemra biosimilar). Indications are △rheumatoid arthritis △giant cell arteritis △systemic type juvenile arthritis △polyarticular type juvenile arthritis △cytokine release syndrome △coronavirus infection-19.
②Hyundai Pharmaceutical resolves to convene a general shareholders’ meeting = Hyundai Pharmaceuticals announced on the 13th that it will hold a regular shareholders’ meeting on the 29th. At this shareholders’ meeting, the appointment of outside director Jeon Byeong-jun, approval of financial statements, and audit report are scheduled. Additionally, the company plans to pay a cash dividend of 35 won per share, which will also be decided at this shareholders’ meeting.
③Daewoong, change in sales or profit/loss structure by more than 30% (15% for large corporations) = Daewoong announced on the 13th that its sales or profit structure had changed by more than 30% (15% for large corporations). Last year’s sales were KRW 1.8138 trillion, and operating profit was KRW 195.6 billion, a 5.7% decrease compared to the previous fiscal year. During the same period, net profit increased by 57.2% to 189 billion won. The company said that its profitability has improved due to the launch and sales increase of its subsidiary’s innovative new drugs (Fexuclu, Enblo), and that its net profit structure has changed due to the expansion of Nabota’s global market and global technology exports.
④HLB Life Sciences, sales or profit/loss structure fluctuating by more than 30% (15% for large corporations) = HLB Life Science announced on the 13th that its sales or profit and loss structure had changed by more than 30% (15% for large corporations). Last year’s sales decreased by 1.74% to KRW 97.9 billion, and operating loss during the same period increased by 20.64% to KRW 24.3 billion. However, the net profit for the period turned into a surplus at 4.5 billion won. The company announced that its operating loss increased due to the coronavirus pandemic, and that its net profit turned into surplus due to an increase in valuation profits from financial assets held.
⑤ Kyungnam Pharmaceutical, adjustment of conversion price = Kyungnam Pharmaceutical announced on the 13th that it had adjusted the conversion price from 1,609 won to 1,335 won. The reason for the adjustment is the adjustment of the conversion price due to the decline in the market price.
⑥DTNC, adjustment of conversion price = DT&C announced on the 13th that it had adjusted the conversion price from 5,540 won to 5,013 won. The reason for the adjustment is the adjustment of the conversion price due to the decline in the stock price.
⑦Hugel, clarification on rumors or reports (unconfirmed) = Hugel re-announced on the 13th the ‘CBC Group considers delisting of Hugel’ reported by Bloomberg on July 12, 2022. Hugel’s largest shareholder is Aphrodite Acquisition Holdings LLC, and CBC Group is the joint largest shareholder of Hugel along with Dione Limited. The company said that the largest shareholder is reviewing strategic plans in relation to the company’s governance structure, but that no decision has been confirmed as of now, as time is needed to make decisions on important issues considering various interests.
⑧Daehan Pharmaceutical decides on cash and in-kind dividends = Daehan Pharmaceutical announced on the 13th that it had decided to pay a cash dividend of 750 won per share of common stock. The dividend record date is December 31st, and the scheduled date for the general shareholders’ meeting is the 28th of next month.
⑨Gemvax decides to approve clinical trial plan, etc. = Gemvax announced on the 13th that it received approval for the U.S. phase 2b clinical trial (IND) for ‘GV1001 (development code name)’ as a treatment for progressive supranuclear palsy. The application date was December 16th last year, and the approval date was the 8th. Clinical trials will be conducted at 30 to 40 hospitals in the United States. The purpose of the clinical trial is to evaluate the safety of GV1001 in patients with progressive supranuclear palsy.
⑩Pharmexin, extension of the investigation period to determine whether it is subject to substantive review = Phambsin announced on the 13th that it is reviewing whether it is subject to a substantive review for listing eligibility and will decide whether it is eligible by March 6 and provide guidance on whether to continue or lift the trading suspension.
⑪Bio Plus, cash and in-kind dividend decision = Bioplus announced on the 13th that it would pay a cash dividend of 70 won per common stock. The dividend record date is December 31 of last year.
⑫GI Innovation, change in sales or profit/loss structure of more than 30% (15% for large corporations) = GI Innovation announced on the 13th that its sales or profit and loss structure had changed by more than 30% (15% for large corporations). Last year’s sales were 5.3 billion won, a 52% increase compared to 2022, operating loss was 53.6 billion won, and net loss for the period was 54.4 billion won. Operating loss and net loss decreased by 21.1% and 31.8%, respectively. The company said that sales increased due to the signing of a technology transfer agreement for the development and commercialization rights to GI-301, an allergy treatment, in Japan, and that operating profit and loss changed due to improved operating loss due to a decrease in current research and development expenses.
⑬HK InnoN, sales (provisional) performance (fair disclosure) = HK InnoN announced on the 13th that sales in 2023 were KRW 828.9 billion, a 2.1% decrease from the previous year, operating profit during the same period was KRW 65.9 billion, a 25.5% increase, and net profit was KRW 47.2 billion, a 23.8% increase.
⑭Chong Kun Dang Holdings, change in sales or profit/loss structure by more than 30% (15% for large corporations) = Chong Kun Dang Holdings announced on the 13th that its sales or profit structure had changed by more than 30% (15% for large corporations). Last year, consolidated sales amounted to KRW 879.8 billion, a 3.2% decrease from the previous year, operating profit turned into a surplus at KRW 17 billion, and net profit also turned into a surplus at KRW 49.4 billion. The company stated that management reform, including a reduction in SG&A expenses, and an increase in equity method profits due to technology exports (CKD-510) from its subsidiary (Chong Kun Dang) played a role.
⑮Curacle, change in sales or profit/loss structure by more than 30% (15% for large corporations) = Curacle announced on the 13th that its sales or profit and loss structure had changed by more than 30% (15% for large corporations). Last year’s sales were KRW 10.5 billion, a 193.7% increase over the previous year, operating loss was KRW 9.8 billion, and net loss for the period was KRW 10.9 billion. Operating loss and net loss decreased by 18.2% and 4.84%, respectively.
⑯Engenbio, sales or profit/loss structure fluctuating by more than 30% (15% for large corporations) = NGenBio announced on the 13th that its sales or profit and loss structure had changed by more than 30% (15% for large corporations). Last year’s sales were KRW 4.4 billion, a 60.5% decrease from the previous year, operating loss was KRW 13.4 billion, and net loss for the period was KRW 13.2 billion. The company said that sales and operating profit decreased due to a decrease in personal genetic testing sales.
⑰Vaxell Bio signs YBL-007 technology introduction contract = Vaxcell Bio announced on the 13th that it signed a contract with YBiologics to introduce YBL-007 technology. The content of the contract is the acquisition of licenses for research, development and commercialization of CAR-T and CAR-NK using YBL-007 sequence genes and proteins.
⑱BC World Pharmaceutical, change in sales or profit/loss structure by more than 30% (15% for large corporations) = BC World Pharmaceutical announced on the 13th that its sales or profit structure had changed by more than 30% (15% for large corporations). Last year’s consolidated sales were KRW 75.1 billion, a 3.3% increase over the previous year, operating profit during the same period was KRW 6.4 billion, a 241.9% increase, and net profit was KRW 2.9 billion, a 4738.6% increase. The main cause of changes in sales or profit structure is explained as the conversion of business profits to surplus due to expansion of domestic market share for new products and flagship products and improvement in profitability.
1707827110
#HIT알공 #InnoN #sales #year #KRW #billion.. #Operating #profit #increased #KRW #billion
